Best CAR-T CDMOs in Japan
· updated as new inspection, certificate, and trial data enters the platform
5
CDMOs tracked
5
Fully scored
2
With FDA records
3
FDA inspections
29
EMA/MHRA GMP certs
CAR-T CDMOs manufacture engineered T-cell products, combining viral-vector transduction, T-cell activation and expansion, and rapid release testing — usually as autologous, per-patient batches on tight vein-to-vein timelines.
Choosing a CAR-T CDMO depends on autologous vs allogeneic experience, in-house vs sourced vector, closed-system processing, and chain-of-identity logistics, alongside a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 1 NAI (no action), 2 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (18), Germany (5), UNITED STATES (4), United States (3), Italy (2).
Last updated 2026-08-18. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 2 insp · 23 GMP | Available | 2 programs |
| 2 |
MN
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.5 | 100.0 | 1 insp · 6 GMP | Limited | 0 programs |
| 3 |
HG
Hitachi Global Life Solutions (CGT)
Yokohama, Japan
|
63.0 | — | — | — | 0 programs |
| 4 |
Minaris (WuXi Advanced Therapies)
Philadelphia, PA / Yokohama, Japan
|
60.5 | — | — | — | 0 programs |
| 5 |
TR
Takara Bio
Kusatsu, Shiga Prefecture, Japan
|
59.5 | — | — | — | 8 programs |
What to evaluate in a CAR-T CDMO
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
How does Japan's regenerative medicine regulatory framework affect cell and gene therapy CDMOs?
Japan operates one of the most developed advanced-therapy regulatory frameworks globally, distinguishing between three product classes with tailored requirements: regenerative medical products, cellular/tissue-based products, and gene therapy products. The framework's conditional and time-limited early approval pathway (introduced 2014, revised 2024) has accelerated advanced-therapy commercialization in Japan compared to most other markets. For CDMOs, this means Japanese advanced-therapy manufacturers have accumulated real experience with regulatory-supported early commercial supply — a signal that materially differs from the more restrictive US and EU pathways. Cross-reference with cell therapy, AAV, and cell & gene therapy umbrella pages for Japanese CDMO capability at the modality level.
PMDA regulatory posture — how does it compare to FDA and EMA?
PMDA GMP is generally regarded as tier-equivalent to FDA and EMA — inspections are rigorous, the framework is well-documented, and PMDA participates in the PIC/S mutual-recognition framework alongside EMA and other major regulators. For Japanese-manufactured product supplying US or EU markets, the qualifying signal is FDA or EMA inspection posture on the specific facility (not just PMDA certification), because FDA and EMA conduct their own facility inspections regardless of PMDA status. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly. Japanese CDMOs supplying global markets typically hold cross-jurisdictional certification.
Which Japanese CDMOs supply US and European markets?
The Japanese CDMOs with US and EU inspection posture typically operate global site networks or maintain FDA-inspected export facilities. Cross-check with the US region ranking and Europe region ranking to identify Japanese CDMOs appearing across regions — these have demonstrated multi-jurisdictional inspection posture. Individual profile pages surface facility-level detail on which specific Japanese sites carry which regulatory certifications.
CAR-T CDMOs — Frequently Asked Questions
Who are the top CAR-T CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked CAR-T CDMOs include AGC Biologics, Minaris Advanced Therapies, Hitachi Global Life Solutions (CGT). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many CAR-T CDMOs have FDA inspection records?
CDMO Signal tracks 2 CAR-T CDMOs with FDA inspection records and 29 EMA/MHRA GMP certificates across the group.
What should I look for in a CAR-T CDMO?
Confirm vector supply (in-house or coordinated), autologous logistics and vein-to-vein turnaround, closed-system scalable processing for parallel patients, and a clean FDA and EMA/MHRA record.
Do CAR-T CDMOs make their own viral vectors?
Some produce lentiviral or retroviral vector in-house; others coordinate an external vector CDMO. In-house vector can shorten timelines and de-risk supply. Check each profile's modality coverage above.
Related modalities